IP Library Granted Patent US 9,163,059
Granted Patent B2
US 9,163,059 · App. 13/664,304 · Granted Oct 20, 2015

Methods for preparing 17-alkynyl-7-hydroxy steroids and related compounds-2

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,163,059
App. No.
13/664,304
Granted
Oct 20, 2015
Kind
B2
Abstract

The invention relates to processes for preparing 17-alkynyl-7-hydroxy-steroids, such as 17-Ethynyl-10R,13S-dimethyl 2,3,4,7,8R,9S,10,11,12,13,14S,15,16,17-hexadecahydro-1H-cyclopenta[a]phenanthrene-3R,7R,17S-triol (also referred to as 17α-ethynyl-androst-5-ene-3β,7β,17β-triol), that are essentially free of process impurities having binding activity at nuclear estrogen receptors.

Claims (10)

1. A process for preparation of 17α-ethynyl-androst-5-ene-3β,7β,17β-triol essentially free of 17α-ethynyl-androst-5-ene-3β,17β-diol comprising the steps of

(a) contacting a suitably protected androst-5-en-7,17-dione having the structure

with a reducing agent to convert the ═O (ketone) functional group at position 7 to hydroxy predominately in the β-configuration;

(b) converting the oxime at position 17 in the reaction product from step (a) to the ═O (ketone) functional group;

(c) converting the acyloxy group in the reaction product from step (b) to 3β-hydroxy;

(d) converting the hydroxy groups at positions 3 and 7 in the product from step (c) to Me 3 SiO— groups; and

(e) contacting the reaction product from step (d) with lithium trimethylsilyl-acetylide to introduce an ethynyl substituent at position 17 predominately in the α-configuration by addition of the acetylide to the ═O (ketone) functional group at position 17,

wherein 17α-ethynyl-androst-5-ene-3β,7β,17β-triol is obtained essentially free of 17α-ethynyl-androst-5-ene-3β,17β-diol.

2. The process of claim 1 comprising the additional step of purifying 17α-ethynyl-androst-5-ene-3β,7β,17β-triol product by recrystallization.

3. The process of claim 2 wherein the 17α-ethynyl-androst-5-ene-3β,7β,17β-triol product is purified by recrystallization from methanol-water.

Assignments (11)
RELEASE OF SECURITY INTEREST Recorded Dec 6, 2024
From: AVENUE VENTURE OPPORTUNITIES FUND, L.P.
To: BIOVIE INC.
Reel/Frame 069510/0814 →
SECURITY INTEREST Recorded Dec 7, 2021
From: BIOVIE INC.
To: AVENUE VENTURE OPPORTUNITIES FUND, L.P.
Reel/Frame 058329/0389 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2021
From: NEURMEDIX, INC.
To: NEURMEDIX, LLC
Reel/Frame 057116/0336 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2021
From: NEURMEDIX, LLC
To: NEURMEDIX, INC.
Reel/Frame 057116/0362 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2021
From: NEURMEDIX, INC.
To: BIOVIE INC.
Reel/Frame 057116/0451 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 29, 2016
From: HARBOR THERAPEUTICS, INC.
To: RESERVA LLC
Reel/Frame 037642/0639 →
CHANGE OF NAME Recorded Jan 29, 2016
From: HOLLIS-EDEN PHARMACEUTICALS, INC.
To: HARBOR BIOSCIENCES, INC.
Reel/Frame 037617/0811 →
MERGER AND CHANGE OF NAME Recorded Jan 29, 2016
From: HARBOR BIOSCIENCES, INC.; HARBOR DIVERSIFIED, INC .
To: HARBOR DIVERSIFIED, INC .
Reel/Frame 037618/0033 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 29, 2016
From: HARBOR DIVERSIFIED, INC .
To: HARBOR THERAPEUTICS, INC.
Reel/Frame 037618/0495 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 25, 2015
From: RESERVA LLC
To: NEURMEDIX INC.
Reel/Frame 035026/0292 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 17, 2013
From: WHITE, STEVEN K.; GE, YU; HUANG, YUJIN
To: HOLLIS EDEN PHARMACEUTICALS, INC.
Reel/Frame 031225/0807 →